Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.38 and traded as low as $2.18. Oramed Pharmaceuticals shares last traded at $2.30, with a volume of 106,083 shares changing hands.
Analyst Ratings Changes
ORMP has been the subject of several recent analyst reports. HC Wainwright restated a "neutral" rating on shares of Oramed Pharmaceuticals in a research note on Monday, September 9th. StockNews.com downgraded Oramed Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, November 11th.
Check Out Our Latest Analysis on Oramed Pharmaceuticals
Oramed Pharmaceuticals Price Performance
The stock's fifty day simple moving average is $2.37 and its 200-day simple moving average is $2.38. The stock has a market cap of $92.31 million, a P/E ratio of 4.51 and a beta of 1.77.
Institutional Investors Weigh In On Oramed Pharmaceuticals
Hedge funds have recently made changes to their positions in the business. Murchinson Ltd. raised its holdings in shares of Oramed Pharmaceuticals by 23.2% during the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company's stock valued at $4,369,000 after buying an additional 320,495 shares during the last quarter. BML Capital Management LLC raised its holdings in shares of Oramed Pharmaceuticals by 62.1% during the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company's stock valued at $5,334,000 after buying an additional 837,153 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Oramed Pharmaceuticals during the first quarter valued at approximately $68,000. Dimensional Fund Advisors LP raised its holdings in shares of Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company's stock valued at $81,000 after buying an additional 10,774 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Oramed Pharmaceuticals during the second quarter valued at approximately $40,000. Institutional investors own 12.73% of the company's stock.
About Oramed Pharmaceuticals
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Recommended Stories
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
